Sanofi India Limited

BSE:500674 Stock Report

Market Cap: ₹140.1b

Sanofi India Valuation

Is 500674 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 500674 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 500674 (₹6081.15) is trading above our estimate of fair value (₹1762.94)

Significantly Below Fair Value: 500674 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 500674?

Key metric: As 500674 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 500674. This is calculated by dividing 500674's market cap by their current earnings.
What is 500674's PE Ratio?
PE Ratio26.4x
Earnings₹5.30b
Market Cap₹140.05b

Price to Earnings Ratio vs Peers

How does 500674's PE Ratio compare to its peers?

The above table shows the PE ratio for 500674 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average38x
GLS Glenmark Life Sciences
31.2x23.4%₹132.7b
532482 Granules India
27.1x22.1%₹133.7b
CONCORDBIO Concord Biotech
63.5x26.9%₹198.9b
530019 Jubilant Pharmova
30.2x5.5%₹179.1b
500674 Sanofi India
26.4x-2.6%₹140.1b

Price-To-Earnings vs Peers: 500674 is good value based on its Price-To-Earnings Ratio (26.4x) compared to the peer average (38x).

Price to Earnings Ratio vs Industry

How does 500674's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.6xn/aUS$72.78m
524652 Ind-Swift
2xn/aUS$13.52m
No more companies available in this PE range
500674 26.4xIndustry Avg. 32.2xNo. of Companies19PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 500674 is good value based on its Price-To-Earnings Ratio (26.4x) compared to the Indian Pharmaceuticals industry average (32.2x).

Price to Earnings Ratio vs Fair Ratio

What is 500674's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

500674 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio26.4x
Fair PE Ratio27.6x

Price-To-Earnings vs Fair Ratio: 500674 is good value based on its Price-To-Earnings Ratio (26.4x) compared to the estimated Fair Price-To-Earnings Ratio (27.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 500674 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹6,081.15
₹8,112.75
+33.4%
9.4%₹9,345.00₹7,421.00n/a4
Nov ’25₹6,773.55
₹8,176.25
+20.7%
8.6%₹9,345.00₹7,560.00n/a4
Oct ’25₹7,073.25
₹8,176.25
+15.6%
8.6%₹9,345.00₹7,560.00n/a4
Sep ’25₹6,809.10
₹8,176.25
+20.1%
8.6%₹9,345.00₹7,560.00n/a4
Aug ’25₹6,586.90
₹8,501.00
+29.1%
10.7%₹9,800.00₹7,560.00n/a5
Jul ’25₹6,552.25
₹9,350.80
+42.7%
13.7%₹11,500.00₹7,984.00n/a5
Jun ’25₹8,637.25
₹9,842.40
+14.0%
11.4%₹11,500.00₹8,125.00n/a5
May ’25₹8,324.10
₹9,497.60
+14.1%
11.1%₹11,300.00₹8,125.00n/a5
Apr ’25₹8,108.55
₹9,497.60
+17.1%
11.1%₹11,300.00₹8,125.00n/a5
Mar ’25₹8,669.30
₹9,370.80
+8.1%
11.1%₹11,300.00₹8,125.00n/a5
Feb ’25₹8,792.10
₹8,611.80
-2.1%
6.6%₹9,175.00₹7,850.00n/a5
Jan ’25₹8,132.05
₹8,391.80
+3.2%
11.0%₹9,175.00₹6,750.00n/a5
Dec ’24₹8,215.50
₹8,391.80
+2.1%
11.0%₹9,175.00₹6,750.00n/a5
Nov ’24₹7,595.80
₹7,490.60
-1.4%
6.5%₹8,028.00₹6,750.00₹6,773.555
Oct ’24₹7,206.50
₹7,287.17
+1.1%
8.7%₹8,028.00₹6,270.00₹7,073.256
Sep ’24₹7,101.90
₹7,287.17
+2.6%
8.7%₹8,028.00₹6,270.00₹6,809.106
Aug ’24₹6,996.80
₹7,211.86
+3.1%
9.5%₹8,213.00₹6,270.00₹6,586.907
Jul ’24₹6,907.20
₹7,138.83
+3.4%
10.5%₹8,213.00₹6,270.00₹6,552.256
Jun ’24₹6,845.20
₹7,138.83
+4.3%
10.5%₹8,213.00₹6,270.00₹8,637.256
May ’24₹5,572.25
₹6,502.83
+16.7%
5.1%₹6,900.00₹5,900.00₹8,324.106
Apr ’24₹5,739.90
₹6,501.17
+13.3%
5.1%₹6,900.00₹5,900.00₹8,108.556
Mar ’24₹5,813.20
₹6,501.17
+11.8%
5.1%₹6,900.00₹5,900.00₹8,669.306
Feb ’24₹5,442.55
₹7,173.86
+31.8%
11.0%₹8,315.00₹6,170.00₹8,792.107
Jan ’24₹5,849.65
₹7,245.29
+23.9%
10.0%₹8,315.00₹6,320.00₹8,132.057
Dec ’23₹5,689.35
₹7,245.29
+27.3%
10.0%₹8,315.00₹6,320.00₹8,215.507
Nov ’23₹5,634.30
₹7,637.86
+35.6%
10.4%₹8,500.00₹6,320.00₹7,595.807

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Bal Pharma

₹2.1b

Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.

BALPHARMA

₹134.50

7D

11.6%

1Y

27.4%

Mercury Laboratories

₹1.1b

Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.

538964

₹911.45

7D

-3.5%

1Y

18.7%

Venus Remedies

₹3.9b

Engages in the pharmaceutical business in India and internationally.

VENUSREM

₹298.65

7D

-1.3%

1Y

-16.9%